Bioethics News

We Don’t Need Greater Access to Nembutal to Achieve Good End-of-Life Care

December 8, 2016

(The Conversation) – In end-of-life care, experienced clinicians today use combinations of multiple treatments to help ease physical and psychological suffering. These treatments may be complex because “suffering” in such settings is not an undifferentiated condition for which there is a single, universally effective therapy such as pentobarbital or morphine. In addition to drugs, counselling, support for family and many other measures are commonly required. The use of these treatments often requires considerable skill.  Not only is the argument for the need for euthanasia wrong, but legalising euthanasia, and Nembutal with it, is likely to be counterproductive. This is because it will result in limitation of access to appropriate care for the majority of patients who do not satisfy the strict criteria for euthanasia.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.